Browse News
Filter News
Found 23 articles
-
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
4/16/2024
Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of NULIBRY.
-
Sentynl Therapeutics Announces Presentation of Study Evaluating the Efficacy and Safety of NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A at 2023 SSIEM Annual Symposium
9/7/2023
Sentynl herapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, announced that data evaluating NULIBRY® (fosdenopterin) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A were presented at the 2023 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Meeting on Aug. 30 in Jerusalem.
-
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
2/23/2023
BridgeBio Pharma, Inc. today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company’s operations.
-
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
11/3/2022
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the third quarter ended September 30, 2022 and provided an update on the Company’s operations.
-
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
9/20/2022
BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. today announced the European Commission (EC) has granted marketing authorization for NULIBRY® (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.
-
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
8/10/2022
BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc., along with partner Medison Pharma announced that the State of Israel Ministry of Health has approved NULIBRY® for Injection as the first therapy in Israel to treat MoCD Type A with the indication to reduce the risk of mortality for patients with molybdenum cofactor deficiency Type A.
-
BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update
8/4/2022
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the second quarter ended June 30, 2022, and provided an update on the Company’s operations.
-
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
7/25/2022
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), and Sentynl Therapeutics, Inc. (Sentynl), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the European Commission authorize marketing under exceptional circumstances for NULIBRY.
-
National Organization for Rare Disorders (NORD) honors NULIBRY® (fosdenopterin) for the Treatment of molybdenum cofactor deficiency (MoCD) Type A with 2022 Industry Innovation Award
6/27/2022
Sentynl Therapeutics, Inc. (Sentynl), today announced that NULIBRY (fosdenopterin) was honored with a 2022 Industry Innovation Award by the National Organization for Rare Disorders (NORD).
-
BridgeBio said it would sell the voucher for $110 million but did not disclose the identity of the company planning to acquire the voucher.
-
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
5/13/2022
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has entered into a definitive agreement with an undisclosed purchaser to sell its PRV for $110 million.
-
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
5/5/2022
BridgeBio Pharma, Inc. today reported its financial results for the first quarter ended March 31, 2022 and provided an update on the Company’s operations.
-
Sentynl Therapeutics Announces Continued Availability of NULIBRY® (fosdenopterin) and the Launch of Sentynl Cares™ Patient Access Program.
4/25/2022
Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the continued availability of NULIBRY (fosdenopterin) for Injection and the launch of Sentynl Cares.
-
BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)
3/8/2022
BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd., announced the execution of an asset purchase agreement for the sale of BridgeBio’s NULIBRY™ for Injection.
-
Based on BridgeBio's current pipeline of programs, this total amount will be sufficient to carry over 30 drug development and discovery programs well into 2024.
-
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update
8/5/2021
BridgeBio Pharma, Inc. today reported its financial results for the second quarter ended June 30, 2021 and provided an update on the Company's operations.
-
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
5/28/2021
BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug Administration (FDA) has approved TRUSELTIQ™ (infigratinib) under the accelerated approval program for the treatment of patients with previously-treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement
-
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
5/6/2021
– Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency ( MoCD) Type A – Reported pr oof-of-concept data of encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) –
-
Alexion Reports First Quarter 2021 Results
4/30/2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021. Total revenues in the first quarter were $1,636.5 million, a 13 percent increase compared to the same period in 2020.
-
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry During the Week of Rare Disease Day 2021
3/8/2021
Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.